Satellos to Present at the Stifel 2023 Healthcare Conference
02 November 2023 - 10:00PM
Business Wire
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV:
MSCL) (OTCQB: MSCLF), a public biotech company developing new small
molecule therapeutic approaches to improve the treatment of muscle
diseases and disorders, announced today that management will
present and participate in the Stifel 2023 Healthcare Conference
taking place November 14 and 15 in New York City.
Mr. Frank Gleeson, Co-founder and CEO of Satellos, will provide
a corporate presentation on Tuesday November 14, 2023, at 1:15 p.m.
ET and will participate in one-on-one meetings during the
conference along with Ms. Elizabeth Williams, CFO of Satellos. To
access a webcast of the panel presentation live or for 90 days
after the event, please click here.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to
developing life-improving medicines to treat degenerative muscle
diseases. Satellos has incorporated breakthrough research in muscle
stem cell polarity into a proprietary discovery platform, called
MyoReGenXTM, to identify degenerative muscle diseases where
deficits in this process affect muscle regeneration and are
amenable to therapeutic intervention. With this platform, Satellos
is building a pipeline of novel therapeutics to correct muscle stem
cell polarity and promote the body’s innate muscle repair and
regeneration process. The Company’s lead drug candidate is an oral,
small molecule in development as a potential disease-modifying
treatment for Duchenne muscular dystrophy. Satellos is
headquartered in Toronto, Ontario. For more information, visit
www.satellos.com.
No regulatory authority has approved or disapproved the
content of this press release. Neither the TSX Venture Exchange nor
its Regulatory Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102609185/en/
Investors: Liz Williams, ir@satellos.com Business Development:
Ryan Mitchell, Ph.D., bd@satellos.com Media: Jessica Yingling,
Ph.D., jessica@litldog.com, +1.858.344.8091
Satellos Bioscience (TSXV:MSCL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Satellos Bioscience (TSXV:MSCL)
Historical Stock Chart
From Dec 2023 to Dec 2024
